drugset
Drugs / Ganfeborole
last change May 2025 re-read 2 minutes ago

Ganfeborole

English name ganfeborole
also known as GSK3036656 · Ganfeborol · GSK-070 FREE BASE · GSK-3036656 FREE BASE · GSK-656 FREE BASE

Small molecule

Developed for
tuberculosis · pulmonary tuberculosis
Investigated by
GlaxoSmithKline · Radboud University Medical Center · University College, London · University of California, San Francisco · Click-TB Consortium · Critical Path Institute
+27 more · European Lung Foundation · European Respiratory Society · Find · German Center for Infection Research · Helmholtz Zentrum München · Instituto de Saude Publica da Universidade do Porto · Janssen, LP · KNCV Tuberculosis Foundation · LigaChem Biosciences, Inc. · London School of Hygiene and Tropical Medicine · Ludwig-Maximilians - University of Munich · Lygature · Michael Hoelscher · Otsuka Pharmaceutical Development & Commercialization, Inc. · Research Center Borstel · Research Institute for Development · TASK Applied Science · TB Alliance · Tuberculosis Network European Trialsgroup · University of Cambridge · University of Hamburg-Eppendorf · University of Liverpool · University of Milano · University of Oxford · University of St Andrews · Uppsala University · Vita-Salute San Raffaele University

Trials 6 · a red edge is where a trial was stopped

today NCT06354257 · Ph 1 NCT06114628 · Ph 2 NCT05807399 · Ph 2 NCT05382312 · Ph 2 NCT03557281 · Ph 2 NCT03075410 · Ph 1
201720182019202020212022202320242025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 12 trials
Phase 1 NCT06354257 Apr → Jul 2024 tuberculosis GlaxoSmithKline Completed No outcome recorded
Phase 1 NCT03075410 Apr → Aug 2017 tuberculosis GlaxoSmithKline Completed No outcome recorded
Phase 24 trials
Phase 2 NCT06114628 Jan 2024 → Feb 2027 expected pulmonary tuberculosis University College, London Recruiting No outcome recorded
Phase 2 NCT05807399 Apr 2023 → Oct 2027 expected pulmonary tuberculosis Michael Hoelscher Recruiting No outcome recorded
Phase 2 NCT05382312 Jul 2022 → May 2025 tuberculosis GlaxoSmithKline Completed No outcome recorded
Phase 2 NCT03557281 Mar 2019 → Dec 2021 tuberculosis GlaxoSmithKline Completed No outcome recorded

Evidence & citations 9 cited values

Every value below carries the sentence it was read from. 9 sources stand behind the page.

FieldValueCited text
Known as ganfeborole “GSK3036656 (ganfeborole) is a first-in-class benzoxaborole inhibiting the Mycobacterium tuberculosis leucyl-tRNA synthetase.” PMID 38365949 ↗ Feb 2024
2

NCT05807399 ↗

NCT06114628 ↗
Known as Ganfeborol ChEMBL registry synonym — accepted as the source's own label CHEMBL4116378 ↗
Known as GSK-070 FREE BASE ChEMBL registry synonym — accepted as the source's own label CHEMBL4116378 ↗
Known as GSK-3036656 FREE BASE ChEMBL registry synonym — accepted as the source's own label CHEMBL4116378 ↗
Known as GSK-656 FREE BASE ChEMBL registry synonym — accepted as the source's own label CHEMBL4116378 ↗
Known as GSK3036656 “Ganfeborole (GSK3036656)” NCT05807399 ↗
4

NCT03557281 ↗

NCT03075410 ↗

NCT05382312 ↗

NCT06354257 ↗
Action Inhibit “a leucyl-tRNA synthetase inhibitor” PMID 31182528 ↗ Jul 2019
Modality Small molecule — CHEMBL4116378 ↗
Route Oral “single and repeat oral doses of GSK3036656” PMID 31182528 ↗ Jul 2019